JP2024508372A5 - - Google Patents
Info
- Publication number
- JP2024508372A5 JP2024508372A5 JP2023546027A JP2023546027A JP2024508372A5 JP 2024508372 A5 JP2024508372 A5 JP 2024508372A5 JP 2023546027 A JP2023546027 A JP 2023546027A JP 2023546027 A JP2023546027 A JP 2023546027A JP 2024508372 A5 JP2024508372 A5 JP 2024508372A5
- Authority
- JP
- Japan
- Prior art keywords
- adhd
- compound
- compound according
- administered
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2101291.9A GB202101291D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| GB2101292.7 | 2021-01-29 | ||
| GB2101296.8 | 2021-01-29 | ||
| GB2101291.9 | 2021-01-29 | ||
| GBGB2101296.8A GB202101296D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| GBGB2101292.7A GB202101292D0 (en) | 2021-01-29 | 2021-01-29 | Novel treatments |
| PCT/EP2022/052142 WO2022162199A2 (en) | 2021-01-29 | 2022-01-28 | Novel treatments |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024508372A JP2024508372A (ja) | 2024-02-27 |
| JP2024508372A5 true JP2024508372A5 (cg-RX-API-DMAC7.html) | 2025-07-17 |
| JP7891230B2 JP7891230B2 (ja) | 2026-07-16 |
Family
ID=80682355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546027A Active JP7891230B2 (ja) | 2021-01-29 | 2022-01-28 | 注意欠陥/多動性障害の治療又は予防に使用するための化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20240130995A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4284356B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7891230B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022215118A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206935A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3038949T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20250747T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE071725T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL4284356T3 (cg-RX-API-DMAC7.html) |
| RS (1) | RS66934B1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202500238T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022162199A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025093748A1 (en) * | 2023-11-03 | 2025-05-08 | 3Z Pharmaceuticals | Use of a calcium channel blocker in the treatment of adhd |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1030672A1 (en) * | 1997-11-19 | 2000-08-30 | Merck & Co., Inc. | Method for treating attention deficit disorder |
| US20040002500A1 (en) * | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
| AU2004292966A1 (en) | 2003-11-21 | 2005-06-09 | Memory Pharmaceutical Corporation | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors |
| EP1609783A1 (en) * | 2004-06-17 | 2005-12-28 | Neuropharma S.A.U. | Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment |
| WO2008115797A1 (en) * | 2007-03-16 | 2008-09-25 | Pavo, Inc. | Therapeutic compositions and methods |
| US9408837B2 (en) | 2008-05-28 | 2016-08-09 | Kitov Pharmaceutical Ltd. | Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs |
| WO2014041035A1 (en) | 2012-09-11 | 2014-03-20 | Institució Catalana De Recerca I Estudis Avançats | Diagnostic method for detecting an autoimmune disease and related subject-matter |
| WO2014133329A1 (ko) * | 2013-02-27 | 2014-09-04 | 에스케이케미칼 주식회사 | 관절염 치료용 복합 제제 |
| KR20140135676A (ko) * | 2014-10-02 | 2014-11-26 | 한국과학기술원 | 주의력 결핍 과잉 행동 모델 마우스, 상기 모델 마우스를 이용한 집중력 장애 질병 예방 및 완화 효과 검증 방법, 및 비특이적 t―타입 칼슘 억제제를 함유하는 집중력 장애 질병 예방 및 치료용 조성물 |
| BR112020008371A2 (pt) * | 2017-10-27 | 2020-11-03 | Esteve Pharmaceuticals, S.A. | novos derivados de alcoxiamino para tratamento de dor e condições relacionadas à dor |
| WO2020120606A1 (en) * | 2018-12-12 | 2020-06-18 | Esteve Pharmaceuticals, S.A. | New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions |
-
2022
- 2022-01-28 WO PCT/EP2022/052142 patent/WO2022162199A2/en not_active Ceased
- 2022-01-28 EP EP22708379.7A patent/EP4284356B1/en active Active
- 2022-01-28 ES ES22708379T patent/ES3038949T3/es active Active
- 2022-01-28 RS RS20250624A patent/RS66934B1/sr unknown
- 2022-01-28 SM SM20250238T patent/SMT202500238T1/it unknown
- 2022-01-28 HR HRP20250747TT patent/HRP20250747T1/hr unknown
- 2022-01-28 AU AU2022215118A patent/AU2022215118A1/en active Pending
- 2022-01-28 CA CA3206935A patent/CA3206935A1/en active Pending
- 2022-01-28 HU HUE22708379A patent/HUE071725T2/hu unknown
- 2022-01-28 PL PL22708379.7T patent/PL4284356T3/pl unknown
- 2022-01-28 JP JP2023546027A patent/JP7891230B2/ja active Active
- 2022-01-28 US US18/274,945 patent/US20240130995A1/en active Pending
-
2025
- 2025-06-24 US US19/247,813 patent/US20260199279A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2317817C2 (ru) | Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства | |
| ES2542891T3 (es) | Terapia de combinación para el tratamiento de apnea del sueño asociada con la obesidad | |
| US20100137448A1 (en) | Methods for Treating Neuropsychiatric Disorders with NMDA Receptor Antagonists | |
| WO2002045710A9 (en) | Methods for treating neuropsychiatric disorders with nmda receptor antagonists | |
| JP2016065085A (ja) | モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン | |
| TW200808696A (en) | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | |
| JP2023526517A (ja) | 運動失調症を治療するためのアセチルロイシンと4-アミノピリジン又はアセタゾラミドとの組合せ | |
| JP2025504984A5 (cg-RX-API-DMAC7.html) | ||
| HRP20250747T1 (hr) | Spojevi namijenjeni upotrebi u liječenju poremećaja hiperaktivnosti i nedostatka pažnje | |
| US20160022659A1 (en) | Methods for treating attention deficit hyperactivity disorder using a combination of bupropion ((±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one) and phentermine (2-methyl-1-phenylpropan-2-amine) | |
| Forcen et al. | Ketamine with psychotherapy for the treatment of depression | |
| RU2403922C2 (ru) | Способ восстановительного лечения больных артериальной гипертензией с метаболическими нарушениями | |
| JPS63500796A (ja) | アミノシクロアルキルアミドの抗不整脈剤用途 | |
| CN105012233B (zh) | 一种含有普鲁卡因的用于分娩的组合物及制备方法 | |
| CN101601665A (zh) | 1r,2s-甲氧胺在制备治疗大便失禁和其他相关疾病的药物中的应用 | |
| TWI297605B (en) | 1-amino-alkylcyclohexanes as trypanocidal agents | |
| WO2022007578A1 (zh) | 治疗阿尔茨海默病的组合及其应用 | |
| BR112021005193A2 (pt) | medicamento e combinação para a prevenção, alívio ou tratamento de transtorno de estresse agudo ou transtorno de estresse pós-traumático, e, medicamento para a prevenção, alívio ou tratamento de sintoma de transtorno de estresse pós-traumático | |
| US8013016B2 (en) | Use of acetyl L-carnitine for the treatment of fibromyalgic syndrome | |
| Isdyanta et al. | Respiratory Rehabilitation for A Loss to Follow-Up Pulmonary Tuberculosis Patient with Bilateral Hydropneumothorax: A Case Report | |
| JP6466792B2 (ja) | 注意欠陥/多動性障害(adhd)の治療方法 | |
| Fang et al. | The Effect of Intraoperative Infusion of Different Doses of Esketamine on the Quality of Recovery in Elderly Patients Undergoing Knee Arthroplasty | |
| RU2440812C1 (ru) | Способ лечения гипотонусных дисфоний | |
| MX2012005661A (es) | Tratamiento de exacerbacion aguda de asma y reduccion de probabilidad de hospitalizacion de pacientes que sufren de la misma. | |
| EP1852113A2 (en) | Methods for treating neuropsychiatric disorders with NMDA receptors antagonists |